BNP Paribas Asset Management’s Centessa Pharmaceuticals CNTA Stock Holding History

BNP Paribas Asset Management’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$27.9M	Buy	+702,254	New	+$18M	0.03%	476

Other funds holding CNTA

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

IVLAV

Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BNP Paribas Asset Management's CNTA Position: Q1 2026 in Review

BNP Paribas Asset Management opened a new position in Centessa Pharmaceuticals (CNTA) in Q1 2026: 702,254 shares worth $27.9M. The stake represents 0.03% of the portfolio and ranks #476 among its holdings.

161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

BNP Paribas Asset Management held 702,254 shares of Centessa Pharmaceuticals worth $27.9M as of Q1 2026.
Centessa Pharmaceuticals was a new BNP Paribas Asset Management position in Q1 2026.
Centessa Pharmaceuticals made up 0.03% of BNP Paribas Asset Management's portfolio in Q1 2026, its #476 holding.
161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.